logo

For the Inventor, By the Inventor

Middlesex, United Kingdom

Glaxo Group Limited

Calculating rank
USPTO Granted Patents = 1,170

% Expired Patents = 33.1



Trademarks = 850

Forward Citations = 17,120

Loading Chart...
Loading Chart...

1,328 inventors (with patents filed for the assignee):

goldMedal Paul Kenneth Rand (72 out of 92 patents)

silverMedal Alan Naylor (39 out of 65 patents)

bronzeMedal Ian H Coates (39 out of 41 patents)

4.  Harry Finch (37 out of 47 patents)

5.  Alexander W Oxford (37 out of 58 patents)

6.  John W Clitherow (35 out of 40 patents)

7.  John Bradshaw (34 out of 40 patents)

8.  Michael Birsha Davies (33 out of 37 patents)

9.  Keith Biggadike (31 out of 51 patents)

10.  Michael B Tyers (31 out of 31 patents)

11.  Anthony James Taylor (29 out of 30 patents)

12.  Lawrence H Lunts (29 out of 29 patents)

13.  Peter C North (26 out of 27 patents)

14.  Duncan B Judd (26 out of 26 patents)

15.  David E Bays (25 out of 29 patents)


Core Competencies:
Inhalation Device
Antigen Binding Proteins
Recombinant Proteins
Pharmaceutical Formulations
Muscarinic Receptor Antagonist
β-2 Adrenoreceptor Agonist
Autoimmune Diseases
Respiratory Tract Diseases
Fluid Dispenser
Dentine Hypersensitivity
Drug Dispenser
Oral Care Composition

1,170 patents:

1. RE51082 - Medicament dispenser (2026-10-20),
2. D1104149 - Label set for an inhalation device (2025-12-02),
3. 12466893 - ANTIGEN BINDING PROTEINS (2025-11-11),
4. 12396986 - Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist (2025-08-26),
5. 11667887 - Method of producing a recombinant protein (2023-06-06),
6. 11419945 - Antigen binding proteins (2022-08-23),
7. D938521 - Label set for an inhalation device (2021-12-14),
8. 11116721 - Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol (2021-09-14),
9. 11090294 - Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist (2021-08-17),
10. 10946025 - Compounds (2021-03-16),
11. 10808040 - Modified proteins and peptides (2020-10-20),
12. 10808029 - Antigen binding proteins to oncostatin M (OSM) (2020-10-20),
13. 10703814 - Method of treatment with humanized anti-IL-18 antibodies (2020-07-07),
14. 10696738 - Anti-serum albumin binding variants (2020-06-30),
15. 10633673 - Production methods (2020-04-28),
Company Overview
Glaxo Group Limited, headquartered in Middlesex, GB, specializes in the development and manufacturing of inhalation devices aimed at treating respiratory tract diseases. The company focuses on advanced pharmaceutical formulations, utilizing core technologies such as antigen binding proteins and recombinant proteins. Its research encompasses innovative treatments for autoimmune diseases, leveraging muscarinic receptor antagonists and β-2 adrenoreceptor agonists to enhance patient outcomes in respiratory health.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Glaxo Group Limited USPTO Patent Assignee Logo
1,170 Patents

#1 in Middlesex

#10 in United Kingdom

#878 in the World

Middlesex, GB
Middlesex, United Kingdom

Glaxo Group Limited

Forward Citations = 17,120

1,328 inventors:

goldMedal Paul Kenneth Rand (72 out of 92 patents)

silverMedal Alan Naylor (39 out of 65 patents)

bronzeMedal Ian H Coates (39 out of 41 patents)

4.  Harry Finch (37 out of 47 patents)

5.  Alexander W Oxford (37 out of 58 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Glaxo Group Limited. Retrieved from https://idiyas.com/company/glaxo-group

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…